In a conversation hosted by Flagship Pioneering, our CEO Brian Alexander shares more about Valo’s patient-centric approach to drug discovery and deep commitment to ecosystem-led innovation. Watch the full conversation here: https://lnkd.in/edQwhpMe
About us
Valo is a technology company built to transform drug discovery and development using large-scale data and AI-powered computation. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease.
- Website
-
http://www.valohealth.com
External link for Valo Health
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Lexington, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
Lexington, MA, US
-
Get directions
New York, NY, US
Employees at Valo Health
Updates
-
Valo Health reposted this
Grateful for the opportunity to speak on a panel about the future of precision medicine at Fierce Biotech Week. A clear theme emerged during the discussion: The next era of precision medicine will be defined by better (real essence) classification of the diseases we are trying to develop therapies for. Not syndromic labels. Not nominal classifications. Some diseases like Huntington’s or sickle cell disease are already there and the challenge is where and how to intervene in the causal pathway. Others, like obesity or heart failure, are nominal classifications with several underlying causal chains. Historically, disease classifications have been limited by our ability to observe and notice patterns (human limitation) among patients in the clinic (data limitation). But now we have access to data on millions of patients over 20-30 years, and tools like AI/ML to identify patterns in the that much data so that we can start to uncover causally relevant groups. It’s clear that this new era requires better disease classifications, but there was also clear excitement about innovations in causal inference methods. Adding a causal layer will allow us to better extract information from observational data and provide the framework for generating the preclinical and clinical evidence needed to fill gaps in our understanding of the causal pathways we hope to intervene on. Thank you, Ann DeWitt, Mary Jane Hinrichs, and Carlos Lopez-Espina for a fantastic conversation. And thank you Nandini Kashyap for organizing!
-
-
What scientific advancements are enabling a new era of precision medicine? On May 14, our CEO, Brian Alexander, MD, MPH, will join industry leaders at Fierce Biotech Week to discuss how AI and other emerging technologies are unlocking new possibilities in precision medicine. More on this event: https://lnkd.in/guwi2eXZ Fierce Life Sciences Events
-
-
We learn from patient journeys every day at Valo as we work to unravel the complexity of disease and inform the discovery of new medicines. But it isn’t every day that we have the privilege of hearing directly from someone living with one of the diseases we are working so diligently to impact. We were so fortunate to have Laurie visit us and generously share her personal journey with #ParkinsonsDisease, offering perspective, insight, and inspiration for the work we do every day. #PDAwarenessMonth #ParkinsonsDiseaseAwarenessMonth #ParkinsonsAwareness The Michael J. Fox Foundation for Parkinson's Research
-
-
This #AdminstrativeProfessionalsDay, we recognize the important work of our team members Linda Johnston, Elizabeth Rivera-Rose, Jessica Wagner and Lourdes DeJesus. Your hard work and dedication are a vital part of our mission to transform how we develop new medicines. Thank you for everything you do!
-
-
We’re proud to share that Valo has been named a "Best Place to Work" by the Boston Business Journal! This recognition reflects the intentional culture and ways of working we’ve built together. Our team is eager to learn, deeply collaborative and united in a shared sense of purpose. Thank you to our incredible employees for bringing our culture to life every day. Learn more about life at Valo: https://lnkd.in/e83uC5B3 #BestPlacesToWork #BBJ
-
Valo Health reposted this
We’re excited to participate in Bio-Ball 2026, a charity basketball tournament taking place this June in support of the Special Olympics Massachusetts. Supporting our local community is core to who we are, and we’re proud to join fellow biotech and Special Olympics teams to raise funds and awareness for such an incredible organization. To learn more about Bio-Ball, or to support our team, visit: https://lnkd.in/eJYu4EeW
-
-
We are proud to announce the appointment Christoforos Anagnostopoulos, PhD, C.Stat, to the newly created position of Chief Causal AI Officer. Dr. Anagnostopoulos is a seasoned AI and life sciences innovation leader who will lead the advancement of our human causal biology platform, translating large-scale, real‑world human data into causal insights that inform drug discovery. Welcome, Chris! Read more here: https://lnkd.in/e7XW26fH
-
We’re excited to participate in Bio-Ball 2026, a charity basketball tournament taking place this June in support of the Special Olympics Massachusetts. Supporting our local community is core to who we are, and we’re proud to join fellow biotech and Special Olympics teams to raise funds and awareness for such an incredible organization. To learn more about Bio-Ball, or to support our team, visit: https://lnkd.in/eJYu4EeW
-
-
We’re excited to welcome David Levin, PhD as our new Vice President of Business Development. David brings enthusiasm for our science and deep experience building strategic partnerships across the ecosystem. We're thrilled to have him join the team and look forward to the impact he’ll make as we continue to grow and advance our mission.